Manit Munshi
Researcher
Also affiliated: Harvard University (2017–2020); Tata Memorial Hospital (2017–2018); International Waldenstrom's Macroglobulinemia Foundation (2018); Dana-Farber Cancer Institute (2011–2024); Shaanxi Research Association for Women and Family (2018); Winthrop Rockefeller Foundation (2024); Advanced Centre for Treatment, Research and Education in Cancer (2018)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Manit Munshi's research focuses on Waldenström macroglobulinemia (WM), a rare non-Hodgkin lymphoma. His work investigates therapeutic strategies and the underlying molecular mechanisms of the disease. Munshi has published on the long-term outcomes of ibrutinib monotherapy in treatment-naive WM patients and explored combination therapies, including ibrutinib with venetoclax or ulocuplumab.
His investigations extend to understanding drug resistance and identifying predictive markers for treatment response. Munshi has examined the efficacy of novel inhibitors like KIN-8194 in overcoming resistance to existing therapies, particularly in MYD88-driven lymphomas. He has also addressed challenges in diagnostic accuracy for WM, specifically concerning the detection of specific mutations like MYD88L265P and CXCR4 mutations using next-generation sequencing.
With a scholarly record including 70 publications and 1,505 citations, Munshi maintains an active research presence. He collaborates with colleagues at the University of Arkansas for Medical Sciences, including Guido Tricot, David E. Mery, and Maurizio Zangari, on studies related to WM and related hematologic malignancies.
Metrics
- h-index: 20
- Publications: 70
- Citations: 1,524
Selected Publications
-
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)
-
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS (2023)
Collaboration Network
Top Collaborators
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
Similar Researchers
Based on overlapping research topics